Maze Therapeutics shareholders re-elect two directors, ratify auditor at 2026 annual meeting

Maze Therapeutics, Inc.

Quorum of 44,660,029 shares (89.75% of outstanding) present at June 8 meeting.
Jason Coloma re-elected with 35,792,536 votes for, 5,926,467 withheld.
Neil Kumar re-elected with 34,056,425 votes for, 7,662,578 withheld.
Ratification of Ernst & Young as auditor passed: 44,557,778 for, 728 against.
No broker non-votes on auditor ratification; 2,941,026 broker non-votes on director election.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Maze Therapeutics, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-08

Exact text from the filing

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm. Votes For Votes Against Abstentions Broker Non-Votes 44,557,778 728 101,523 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Maze Therapeutics, Inc. shareholders approved To elect each of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as a Class I director to serve until the Company's 2029 annual meeting of stockholders at the 2026-06-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-08

Exact text from the filing

Proposal 1: Election of Directors. Nominee Votes For Votes Withheld Broker Non-Votes Jason Coloma, Ph.D. 35,792,536 5,926,467 2,941,026 Neil Kumar, Ph.D. 34,056,425 7,662,578 2,941,026

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Maze Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-265858

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.